Cohance Lifesciences Stock Surges 37% in Two Days Following Appointment of New CEO

Cohance Lifesciences Extends Rally to Second Straight Session

Shares of Cohance Lifesciences continued to surge on Tuesday, April 28, extending their rally to a second straight session. The stock jumped as much as 17% intraday, following a 20% increase in the previous session. This sharp rally comes after the company announced the appointment of former Cipla CEO Umang Vohra as Executive Chairman and Group CEO.

The stock's price opened at ₹444.45, higher than the previous close of ₹432.10, and climbed to an intraday high of ₹514.65. Over the past two sessions, the stock has gained about 37%. This significant increase follows the company's announcement of Vohra's appointment, effective May 1 as Executive Chairman and May 20 as Group CEO.

In an exchange filing dated April 27, Cohance Lifesciences announced that Vohra succeeds Vivek Sharma, who stepped down as Executive Chairman for personal reasons. However, Sharma will continue to be with Cohance as an Advisor for the next 9 months and will support a smooth transition. Vohra's appointment reflects a deliberate, strategic decision taken by the Board to bring in a leader whose profile is specifically suited to the demands of the company's transformation and its next phase of growth.

Read also: IBM Shares Decline 8% After Recent Rally, Ending Five-Day Winning Streak

With over three decades of experience, Vohra has led large, complex, global businesses through periods of strategic transformation while maintaining an unwavering focus on customers, quality, and operational excellence. Most recently, as CEO and Managing Director of Cipla Limited, Vohra led the company's transformation over the last decade to build a diversified global pharmaceutical enterprise. Having worked in and transformed two very large and respected Pharma companies in India, Vohra brings an owner-mindset and vast experience in business to the Cohance platform.

Cohance Lifesciences Limited is a technology-led, integrated CDMO platform that provides development and manufacturing solutions across complex APIs, performance materials, agrochemicals, ADCs, oligonucleotides, and advanced chemistries for global pharmaceutical and life sciences clients.

Share Price Comparison

Read also: Investors Including Fidelity, Goldman Sachs and WhiteOak Capital Acquire Lenskart Shares Worth Rs 2,873 Crore

However, the stock has declined 3.37% year-to-date (YTD) and 56% in a year. Looking at the broader level, the stock has been unsuccessful in impressing its long-term investors as it has given only 7% returns in three years. However, it has declined 6.57% in five years.